Nirma Limited has confirmed that it did not create any encumbrance on the shares of Alivus Life Sciences held by it during the financial year 2025-26. The disclosure, addressed to the stock exchanges, states that the promoter group has not pledged or otherwise encumbered its shareholding, either directly or indirectly, throughout the specified period.

The filing was made to comply with Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011. This regulation requires promoters to disclose any encumbrance on shares held by them to ensure transparency for shareholders and the market.

The communication was signed by Paresh Sheth, Company Secretary of Nirma Limited, on April 7, 2026. Copies of the disclosure were also sent to the members of the Audit Committee of Alivus Life Sciences Limited. The company was formerly known as Glenmark Life Sciences Limited.

Alivus Life Sciences has scheduled an analyst and institutional investor meeting in Mumbai for June 16, 2026. The company's representatives will engage with Aditya Birla SunLife MF through a one-on-one session to discuss business performance and strategy. This meeting is part of the company's ongoing investor relations efforts under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.

The meeting will be conducted in person, though the schedule and mode are subject to change due to exigencies on the part of the investor, analyst, or the company.

Meeting Schedule

The disclosure was submitted to the BSE Ltd. and the National Stock Exchange of India Ltd. by Rudalf Corriea, Company Secretary & Compliance Officer of Alivus Life Sciences Limited. The company, formerly known as Glenmark Life Sciences Limited, is headquartered at Technopolis Knowledge Park in Andheri (E), Mumbai.